FDA waiver of user fees
Agency is considering the creation of an industry/agency advisory committee to consider the final rule on the waiver provisions of the User Fee Act of 1992. Speaking at a Drug Information Association Orphan Drug Development Conference in Bethesda, Md. Nov. 2, Office of Chief Mediator and Ombudsman Regulatory Counsel Suzanne O'Shea said it is "the first time FDA has actively considered using [negotiated rulemaking] for issuing a rule." Later, O'Shea indicated that the agency is in the early stages of considering the option. FDA's next step would be to assess, in a formal setting, the suitability of negotiated rulemaking and to determine what are the relevant interests
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth